Testing whether a gene variant affects methotrexate response in psoriatic arthritis
Tests methotrexate against placebo in adults with psoriatic arthritis, linked to a CARD14 gene variant.
Key facts
- Who runs it
- South Valley University
- Where
- Qina, EgyptSee the site
- Trial code
- Registry title
- Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 5 Mar 2025
- Planned end
- 10 Mar 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methotrexate
- Placebo
- Record updated
- 11 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 50 with moderate to severe psoriasis, with or without psoriatic arthritis. It studies a gene change (CARD14) and how people respond to methotrexate.
- Age
- 18 to 50 years
- Sex
- All sexes can join.
- Disease stage
- Moderate to severe psoriasis, diagnosed clinically. The record gives a PASI score from 5-10 % of body surface area, and involvement of greater than 10% of body surface area (BSA). It can come with or without psoriatic arthritis.
- Earlier treatment
- People currently on immunosuppressive or systemic therapies cannot join.
- Biomarker or test result
- The CARD14 gene change rs34367357 is studied. The record does not say that people must have it.
Main reasons for not taking part
- Other autoimmune conditions, such as rheumatoid arthritis or systemic lupus erythematosus
- Pregnancy and breastfeeding
- Liver or kidney impairment
- Allergy to methotrexate or a reason not to take it
- Active or uncontrolled infections, including tuberculosis
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patients aged 18 years and above
- Patients having psoriasis diagnosed clinically and who have a severity grade of moderate to severe, defined as a Psoriasis Area and Severity Index (PASI) score from 5- 10 % of body surface area, and involvement of greater than 10% of the body surface area (BSA) with or without psoriatic arthritis
Who cannot take part
- Patients currently undergoing immunosuppressive or systemic therapies
- Patients with other autoimmune conditions (e.g., rheumatoid arthritis, systemic lupus erythematosus)
- Patients with known genetic disorders affect immune system function
- Patients with liver or kidney impairment
- Patients with allergy or contraindication to methotrexate
- Patients with active or uncontrolled infections, including chronic infections like tuberculosis
- Pregnancy and lactation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in Egypt
- Qina University hospital, South Valley University HospitalQina, EgyptContact: Mohamed Hosny Hassan, ProfessorTaking people
About the trial
What the trial wants to find out
Psoriasis is a chronic, immune-mediated, multisystemic, inflammatory disease caused by the interaction of multiple susceptibility genes and environmental factors that affects 1-3% of the population worldwide .Psoriasis also is a chronic inflammatory skin disease characterized by scaly indurated erythema.
Read full original descriptionShow less
Psoriatic arthritis (PsA) is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms.
The 3 groups in the trial
- Group AExisting treatment, for comparison
About 20 patients with psoriasis
Treatment: Methotrexate
- Group BExisting treatment, for comparison
About 20 psoriatic arthritis
Treatment: Methotrexate
- Group CPlacebo, for comparison
About 10 healthy control group
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient and Its Relation With Response to Methotrexate
- Plain-language title
- Testing whether a gene variant affects methotrexate response in psoriatic arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06870500, who can take part
- Record updated
- 11 March 2025